News | Published:

Drugs with dual-hormone action gain attention in diabetes field

Nature Medicine volume 19, page 1549 (2013) | Download Citation

  • A Correction to this article was published on 07 January 2014

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 07 January 2014

     The December 2013 news story “Drugs with dual-hormone action gain attention in diabetes field” (Nat. Med. 19, 1549, 2013) incorrectly stated that Sanofi withdrew its US application for the diabetes drug lixisenatide owing to concerns over cardiovascular safety. As Sanofi announced in September, the application was actually withdrawn to avoid public disclosure of early interim data that could potentially compromise the integrity of an ongoing clinical trial. The error has been corrected in the HTML and PDF versions of the article.


  1. 1.

    et al. Sci. Transl. Med. 5, 209ra151 (2013).

  2. 2.

    et al. Nat. Med. 18, 1847–1856 (2012).

  3. 3.

    et al. Diabetes 62, 1131–1138 (2013).

  4. 4.

    et al. Br. J. Pharmacol. 165, 2736–2748 (2012).

  5. 5.

    et al. Diabetes 58, 2258–2266 (2009).

  6. 6.

    , , & J. Biol. Chem. doi:10.1074/jbc.M113.512046 (2013).

Download references

About this article

Publication history




  1. Search for Veronica Hackethal in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing